Compare SCYX & BGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCYX | BGI |
|---|---|---|
| Founded | 1999 | 1879 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.6M | 22.7M |
| IPO Year | 2014 | 2005 |
| Metric | SCYX | BGI |
|---|---|---|
| Price | $0.66 | $1.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 563.4K | 23.9K |
| Earning Date | 11-05-2025 | 12-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,932,000.00 | ★ $136,846,182.00 |
| Revenue This Year | $167.73 | N/A |
| Revenue Next Year | $290.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.45 |
| 52 Week Low | $0.57 | $0.56 |
| 52 Week High | $1.49 | $2.03 |
| Indicator | SCYX | BGI |
|---|---|---|
| Relative Strength Index (RSI) | 45.86 | 45.07 |
| Support Level | $0.65 | $1.00 |
| Resistance Level | $0.72 | $1.11 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 54.91 | 57.17 |
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.